NCT02324049View on ClinicalTrials.gov

Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

October 16, 2017

Study Completion Date

October 16, 2017

Conditions
Mucopolysaccharidosis IIIB
Interventions
DRUG

SBC-103

Trial Locations (4)

15224

Pittsburgh

55414

Minneapolis

08950

Barcelona

B4 6NH

Birmingham

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY